PMID- 28433799
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 10
IP  - 3
DP  - 2017 Jun
TI  - Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with 
      Associations to T-Stage and Recurrence.
PG  - 385-395
LID - S1936-5233(17)30031-1 [pii]
LID - 10.1016/j.tranon.2017.03.002 [doi]
AB  - BACKGROUND: Blood-based proteomic profiling may aid and expand our understanding 
      of diseases and their different phenotypes. The aim of the presented study was to 
      profile serum samples from patients with malignant melanoma using affinity 
      proteomic assays to describe proteins in the blood stream that are associated to 
      stage or recurrence of melanoma. MATERIAL AND METHODS: Multiplexed protein 
      analysis was conducted using antibody suspension bead arrays. A total of 232 
      antibodies against 132 proteins were selected from (i) a screening with 4595 
      antibodies and 32 serum samples from melanoma patients and controls, (ii) 
      antibodies used for immunohistochemistry, (iii) protein targets previously 
      related with melanoma. The analysis was performed with 149 serum samples from 
      patients with malignant melanoma. Antibody selectivity was then assessed by 
      Western blot, immunocapture mass spectrometry, and epitope mapping. Lastly, 
      indicative antibodies were applied for IHC analysis of melanoma tissues. RESULTS: 
      Serum levels of regucalcin (RGN) and syntaxin 7 (STX7) were found to be lower in 
      patients with both recurring tumors and a high Breslow's thickness (T-stage 3/4) 
      compared to low thickness (T-stage 1/2) without disease recurrence. Serum levels 
      of methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) were instead elevated 
      in sera of T3/4 patients with recurrence. The analysis of tissue sections with 
      S100A6 and MTHFD1L showed positive staining in a majority of patients with 
      melanoma, and S100A6 was significantly associated to T-stage. CONCLUSIONS: Our 
      findings provide a starting point to further study RGN, STX7, MTHFD1L and S100A6 
      in serum to elucidate their involvement in melanoma progression and to assess a 
      possible contribution to support clinical indications.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Bystrom, Sanna
AU  - Bystrom S
AD  - Affinity Proteomics, SciLifeLab, KTH - Royal Institute of Technology, 171 65 
      Solna, Sweden.
FAU - Fredolini, Claudia
AU  - Fredolini C
AD  - Affinity Proteomics, SciLifeLab, KTH - Royal Institute of Technology, 171 65 
      Solna, Sweden.
FAU - Edqvist, Per-Henrik
AU  - Edqvist PH
AD  - Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 
      Uppsala, Sweden; Science for Life Laboratory, Uppsala University, 751 85 Uppsala, 
      Sweden.
FAU - Nyaiesh, Etienne-Nicholas
AU  - Nyaiesh EN
AD  - Affinity Proteomics, SciLifeLab, KTH - Royal Institute of Technology, 171 65 
      Solna, Sweden.
FAU - Drobin, Kimi
AU  - Drobin K
AD  - Affinity Proteomics, SciLifeLab, KTH - Royal Institute of Technology, 171 65 
      Solna, Sweden.
FAU - Uhlen, Mathias
AU  - Uhlen M
AD  - Affinity Proteomics, SciLifeLab, KTH - Royal Institute of Technology, 171 65 
      Solna, Sweden.
FAU - Bergqvist, Michael
AU  - Bergqvist M
AD  - Centre for Research and Development, Uppsala University, 751 85 Uppsala, Sweden; 
      Region Gavleborg, Gavle sjukhus, 801 88 Gavle, Sweden; Department of Radiation 
      Sciences, Umea University, 901 87 Umea, Sweden.
FAU - Ponten, Fredrik
AU  - Ponten F
AD  - Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 
      Uppsala, Sweden; Science for Life Laboratory, Uppsala University, 751 85 Uppsala, 
      Sweden.
FAU - Schwenk, Jochen M
AU  - Schwenk JM
AD  - Affinity Proteomics, SciLifeLab, KTH - Royal Institute of Technology, 171 65 
      Solna, Sweden. Electronic address: jochen.schwenk@scilifelab.se.
LA  - eng
PT  - Journal Article
DEP - 20170420
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC5403766
EDAT- 2017/04/24 06:00
MHDA- 2017/04/24 06:01
PMCR- 2017/04/20
CRDT- 2017/04/24 06:00
PHST- 2017/01/16 00:00 [received]
PHST- 2017/03/02 00:00 [revised]
PHST- 2017/03/06 00:00 [accepted]
PHST- 2017/04/24 06:00 [pubmed]
PHST- 2017/04/24 06:01 [medline]
PHST- 2017/04/24 06:00 [entrez]
PHST- 2017/04/20 00:00 [pmc-release]
AID - S1936-5233(17)30031-1 [pii]
AID - 10.1016/j.tranon.2017.03.002 [doi]
PST - ppublish
SO  - Transl Oncol. 2017 Jun;10(3):385-395. doi: 10.1016/j.tranon.2017.03.002. Epub 
      2017 Apr 20.